Articles

Immunovant and Wave: A Look at Autoimmune Innovations

This article delves into Immunovant's promising developments in autoimmune diseases and Wave's advancements in RNA editing, highlighting their implications for the pharmaceutical industry.

Novartis Terminates Contract with Porton: Implications for Pharma

Novartis has terminated its contract with Chinese CDMO Porton, raising significant legal and operational questions. This article explores the implications for the pharmaceutical industry.

Marc Tessier-Lavigne Responds to Allegations: Implications for Pharma

Marc Tessier-Lavigne addresses serious allegations from a new book regarding his conduct in the Stanford misconduct case. This article explores the implications for the pharmaceutical sector.

Clinical Research Patient 2026: What to Expect

The Clinical Research Patient event in 2026 promises to be a pivotal gathering for industry professionals. Here's what you need to know ahead of time.

The Current Landscape of Consumer Health: Insights and Implications

This article delves into the evolving landscape of consumer health, highlighting key trends and their implications for pharmaceutical businesses.

23andMe Connects DNA Data with Medical Records: Implications for Pharma

23andMe is now connecting users’ DNA data with their medical records, raising significant implications for the pharmaceutical sector. This article explores the potential impacts and opportunities.

Streamlined R&D at Novo Nordisk: Insights from Research Chief Petersen

Novo Nordisk's research chief, Petersen, discusses how streamlined R&D processes enhance drug discovery efficiency, impacting the pharmaceutical landscape.

Biotech Investors' Mood and FDA Insights: What You Need to Know

This article delves into the current sentiments of biotech investors and insights from a former FDA head, providing actionable intelligence for pharma teams.

WHO's Defense of Ebola Response: Implications for Pharma

The WHO responds to criticism from Marco Rubio regarding its Ebola response efforts, highlighting the challenges and implications for the pharmaceutical industry.

BeOne Launches Campaign with Tim Howard: A Game Changer for Pharma Marketing

BeOne's 'One Save Changes Everything' campaign featuring Tim Howard marks a significant shift in pharmaceutical marketing strategies. This article explores its implications for the industry.

NIH Leadership Gaps: Implications for the Pharma Industry

The NIH currently has 15 of its 27 institutes led by acting directors, raising concerns about leadership stability and its impact on the pharmaceutical sector.

BioMarin Drug Acquisition: Missed Goals in Rare Disease Study

BioMarin's recent drug study results raise questions about future strategies in rare disease treatment and investment implications.

Leadership Challenges at NIH: Implications for Pharma

The NIH faces a leadership vacuum that could impact pharmaceutical innovation and funding. This article explores the implications for industry stakeholders.

WHO Defends Ebola Response Amid Critique from Rubio

The WHO faces scrutiny from Marco Rubio regarding its Ebola response. This article examines the implications for pharmaceutical stakeholders.

The State of Consumer Health: Trends and Implications

This article delves into the evolving landscape of consumer health, highlighting key trends and their implications for pharmaceutical companies.

Supreme Court Decision on IRA Challenges: Implications for Pharma

The Supreme Court's decision not to hear IRA challenges from Novo and AstraZeneca signals significant implications for the pharmaceutical industry, particularly in drug pricing strategies.

The Next Big Pharma Company Will Emerge from China

China's pharmaceutical landscape is evolving rapidly, positioning it as a potential leader in the global market. This article explores the implications for B2B stakeholders.

Kennedy's Leadership Shakeup on Preventive Services Task Force

Kennedy's recent decision to fire two leaders on the preventive services task force raises questions about future strategies and impacts on the pharmaceutical industry.

Oorja Launches New Fibrosis Drugs: Insights from Acceleron Veterans

Oorja, a new biotech startup led by Acceleron veterans, aims to develop innovative fibrosis drugs. This article explores the implications for the pharmaceutical industry.

Amgen's CFO Departure: Implications for Pharma Industry

Amgen bids farewell to its CFO, attracting a Galderma executive with a substantial bonus. This article explores the implications for the pharma industry.